Print Friendly, PDF & Email

NCT/Study#

NA /

MK3475-B96

A Phase 3, Randomized, Double-Blind Study Of Pembrolizumab Versus Placebo In Combination With Paclitaxel With Or Without Bevacizumab For The Treatment Of Platinum-Resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-Ov65)

DISEASE GROUP:
Gynecologic
current phase:
Phase III
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: